Durable Remission of Mantle Cell Lymphoma Relapsing a Third Time After Allogeneic Hematopoietic Stem Cell Transplantation Treated With Rituximab, Bortezomib, Donor Lymphocytes, and Pegylated Interferon

Vo, Phuong; Jaffe, Elaine S.; Cook, Lisa; Ramos, Catalina; Childs, Richard W.

doi:10.1016/j.clml.2013.05.006

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strategies that have had anecdotal success include immunologic approaches (e.g., CD20‐targeted monoclonal antibodies), immunosuppression withdrawal, donor lymphocyte infusion, and second allogeneic HCT. Standard salvage regimens are options for therapy, and interestingly, one case report identified a patient who received donor lymphocyte infusions, interferon, rituximab, and bortezomib at various times for post‐transplant relapse and remained alive 10‐yr postallogeneic transplant despite multiple episodes of relapse . This case illustrates the feasibility of subsequent therapies and that prolonged remissions are possible but uncommon.…”

Section: Management Of Relapse After Allogeneic Transplantmentioning

confidence: 93%

Role of allogeneic stem cell transplantation in mantle cell lymphoma

Cohen

Burns

Bachanová

2014

European J of Haematology

View full text Add to dashboard Cite

Despite a wide spectrum of treatment options, mantle cell lymphoma (MCL) remains a challenging hematologic malignancy to manage. Advances in front-line therapy, including the monoclonal antibody rituximab and increasing use of cytarabine, have improved remission rates. Autologous hematopoietic cell transplantation (HCT) can effectively consolidate remission of MCL, leading to encouraging survival beyond 5 yr. However, nearly all patients with MCL will relapse and require salvage therapy. Novel agents such as ibrutinib, bortezomib, and lenalidomide have dramatically expanded the options for treating relapsed MCL. In this review, we summarize the clinical evidence supporting the use of allogeneic donor HCT in MCL and make recommendations on indications for its use. Data suggest that allogeneic donor HCT is the only curative therapy for patients with poor prognosis or aggressive MCL. Patient selection, timing, and optimal use remain a matter of scientific debate and given the rapidly changing therapeutic landscape of MCL, the outcomes of allogeneic HCT should be interpreted in the context of novel therapeutics.

show abstract

Section: Management Of Relapse After Allogeneic Transplantmentioning

confidence: 93%